TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06595329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned puncture. The epidural space will be identified at the level of the tenth thoracic intervertebral space using the loss of resistance technique and an 18G Tuohy epidural needle. After placing the epidural catheter, 4 ml of local anesthetic Levobupivacaine 0.25% will be administered into the epidural space. After inducing general anesthesia, an additional 4 ml of Levobupivacaine 0.25% will be administered before the surgical incision. Subjects in the control group will receive an infusion of 0.125% Levobupivacaine for 24 hours after the procedure.
Study: NCT03390920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Allograft
Description: The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
Study: NCT04759664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014 Gel (Dose 1)
Description: Topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014 Gel (Dose 2)
Description: Topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LUT014 matching placebo topical gel
Study: NCT06595329

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intrathecal opioid analgesia
Description: After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned intrathecal puncture. Subsequently, at the selected site, the dura will be punctured using a spinal needle (25G Quincke spinal needle), and 0.3 mg of morphine will be administered to the patient. Following the intervention, the patient will be induced into general anesthesia.
Study: NCT06591117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vizio Aqueous Microshunt
Description: Ocular microshunt placement for the treatment of Glaucoma
Study: NCT06591195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distraction by use of kaleidoscope
Description: À kaleidoscope is an optical device consisting of mirrors that reflect images of bits of coloured glass in a symmetrical geometric design through a viewer.~A kaleidoscope was selected as the non-electronic method of distraction, because of its wide availability due to low costs, its evolving and colourful visual stimuli, the fact that is blocks out any visualisations from the environment when used properly, and because it requires active participation (i.e., greater attention) from the subject.
Study: NCT06654635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal plane block
Description: The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: The patients in this group will receive ultrasound -guided Erector spinae plane block after induction of general anesthesia. Erector spinae plane block will be performed at the level of T9 bilaterally.
Study: NCT05788393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: lidocaine group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
Study: NCT04700722

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
Study: NCT04035174

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LTS-2 DEC patch
Description: After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: LTS-2 DEC patch
Description: After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin snips
Description: Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin snips
Description: Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
Study: NCT04834206

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel, nedaplatin, fluorouracil
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.

Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.

Intervention type: DRUG
Group type: OTHER
Intervention: Nedaplatin
Description: Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Study: NCT04268524

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: drug: miltefosine with thermotherapy
Description: see previous

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: drug: miltefosine with thermotherapy
Description: see previous

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: drug: miltefosine with thermotherapy
Description: see previous

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: drug: miltefosine with thermotherapy
Description: see previous
Study: NCT06654635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No block will be performed, and patient will receive general anesthesia (GA) only.
Study: NCT06655584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset Bliss DTX
Description: The patient will be installed in a reception room and will benefit from Bliss DTx digital therapy via a video headset and an audio headset for a duration of 13 minutes
Study: NCT05570123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flexofytol Forte
Description: standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
Study: NCT06655597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: REDS Powder
Description: Dietary supplement powder
Study: NCT06654908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resisted exercise using sand bags,resistance machines and elastic bands
Description: Rehabilitative exercise training will be performed as previously described. All exercises will be performed using free weights, elastic bands and variable-resistance machines. Modifications to exercises will be made when appropriate depending on the patient injury characteristics. The load will be gradually increased from 50-60% of 3RM at the beginning of the program up to 80-85% of 3RM (repetitions maximum) at the end of the program. All exercise sessions will be preceded by a 5-minute warm-up at \&lt;50% VO2peak. No strength training activities will be permitted outside the supervised training session; however, both groups will be encouraged to maintain normal daily activities
Study: NCT06600295

Intervention type: OTHER
Intervention: tests/questionnaires
Description: EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS

Intervention type: OTHER
Intervention: tests/questionnaires
Description: EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS
Study: NCT05570123

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets a day, one in the morning, one in the evening
Study: NCT05407922

Intervention type: PROCEDURE
Intervention: Laparoscopy vs Non-laparoscopy approach
Description: Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen

Intervention type: PROCEDURE
Intervention: Laparoscopy vs Non-laparoscopy approach
Description: Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
Study: NCT06600295

Intervention type: OTHER
Intervention: tests/questionnaires
Description: EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS

Intervention type: BIOLOGICAL
Intervention: biological samples
Description: blood, saliva, tongue mucus

Intervention type: BIOLOGICAL
Intervention: biological samples
Description: blood, saliva, tongue mucus

Intervention type: BIOLOGICAL
Intervention: biological samples
Description: blood, saliva, tongue mucus

Intervention type: OTHER
Intervention: evaluation
Description: strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s

Intervention type: OTHER
Intervention: evaluation
Description: strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s

Intervention type: OTHER
Intervention: evaluation
Description: strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s
Study: NCT06589323

Intervention type: PROCEDURE
Intervention: Coronary artery bypass graft
Description: All patients included will undergo coronary artery bypass graft surgery. During surgery, every graft will be evaluated through transit time flowmetry (TTFM) and intraoperative ultrasound control (HFUS).
Study: NCT06593782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: 1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: 1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolasetron
Description: 1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;
Study: NCT04547153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 200mg/square metre/day civ D1-D21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25mg/square metre ivdrip D1, D8, D15
Study: NCT06592183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-phone based, self-driven speech rehabilitation
Description: Participants will perform the speech exercises for 60 min per day. Participants may complete the speech exercises all at once or split them into several sessions. Thus, participants assigned to the intervention group will use the application for 30-60 min daily, 5 days per week, for 4 consecutive weeks.
Study: NCT06586723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBIS
Description: Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PBIS
Description: Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELM
Description: Helping Educational Leaders Mobilize Evidence (HELM) is an implementation strategy for promoting building-level implementation leadership, implementation climate, and high-fidelity delivery of evidence-based practices
Study: NCT06592131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
Study: NCT06155448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perennial Malaria Chemoprevention effect
Description: Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
Study: NCT04926220

Intervention type: DEVICE
Intervention: Trans-esophageal Doppler monitoring
Description: Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output

Intervention type: DEVICE
Intervention: MostCareUP Haemodynamic Monitor
Description: MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor

Intervention type: DEVICE
Intervention: Argos Cardiac Output (CO) Monitor
Description: Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
Study: NCT06592131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
Study: NCT06592157

Intervention type: OTHER
Intervention: NewEpi Plus Liquid Wound Dressing
Description: 1. Hold the spray nozzle 7-10 cm away from the wound. Apply the product evenly over the wound, with a dosage of one spray (0.1 ml) per 10x10 cm² of wound area.~2. Wait for 2 minutes. It is not necessary to wait until the solution is completely dry; you can proceed with applying ointments and various types of dressings as directed by the physician.~3. Use once a day for 21 days. The frequency of use can be adjusted according to the physician\&#39;s instructions.

Intervention type: OTHER
Intervention: standard wound care
Description: The standard wound care protocol aims to provide comprehensive and systematic care for patients to ensure smooth healing of surgical wounds. These care measures include regular cleaning, disinfection, dressing changes, and continuous observation and assessment of the wound condition. Through strict aseptic techniques and scientific care procedures, standard wound care effectively reduces the risk of infection and promotes wound healing.
Study: NCT06588985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Coaching Parent Training Workshop
Description: Parents will attend a 3-hour online workshop that introduces the fundamentals of emotion coaching and the phone consultations will be used to help parents troubleshoot and brainstorm application of the workshop content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Parents will only receive the parent workshop and phone consultations after they have completed all the required questionnaires.
Study: NCT06601153

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT
Description: Cardiac CT to characterize coronary atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT
Description: Cardiac CT to characterize coronary atherosclerosis
Study: NCT06591871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management educational program for post mastectomy lymphedema women
Description: The researcher created this program in response to the identified needs of post mastectomy lymphedema women to provide them with essential knowledge and self-care practices concerning post-mastectomy lymphedema. It was designed as a straightforward Arabic booklet written in simple language and supplemented with colorful illustrations and images to accommodate women of varying educational levels. It was consisted of two sections:~Theoretical section included the following (A brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors , stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care ,a healthy nutrition and when you call your physician ).~Practical section included (use of compression bandages, garments and their care, upper extremity lymphedema exercises, Manual Lymphatic Drainage (MLD) massage).
Study: NCT06591793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVB-081
Description: Single subretinal administration
Study: NCT05199194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Intravenous thrombolysis with tenecteplase 0.25mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
Study: NCT06591793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVB-081
Description: Single subretinal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVB-081
Description: Single subretinal administration
Study: NCT05733351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study: NCT05417633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Description: Inducing different values of monovision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Description: Inducing different values of monovision
Study: NCT05733351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT05417633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Description: Inducing different values of monovision